Tsewang Tashi
Rating: 4.9 of 5
( out of 89 reviews )

Tsewang Tashi, MD

Languages spoken: English, French, Mandarin Chinese, Hindi, Urdu, Tibetan

Clinical Locations

Primary Location

VA - Building #14

Hematology/Oncology
500 S Foothill Dr
Salt Lake City , UT 84148
801-582-1565
Get Directions

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
2000 Circle of Hope
Salt Lake City , UT 84112
801-585-0236
Get Directions

South Jordan Health Center

5126 West Daybreak Parkway
South Jordan , UT 84009
801-213-4500
Get Directions

  • Dr. Tsewang Tashi joined the University of Utah faculty after completing his hematology/oncology fellowship in 2015. He received his medical degree from Chang Gung University, Taiwan, and completed his internal medicine residency both in Taiwan, and in the US from Creighton University Medical Center, Omaha, NE. Early in his career during fellowship, he has been involved in research with Dr. Josef Prchal on high altitude genetic adaptation, hypoxia signaling and molecular genetics of myeloproliferative neoplasms.

    His research and clinical interest lies in myeloid malignancies and currently sees and manages patients with myeloproliferative neoplasms, including systemic mastocytosis, and acute leukemias, both at the Huntsman Cancer Institute and serving the veterans at the George E. Whalen VA Medical Center in Salt Lake City. He established and currently leads the Mastocytosis Program at the Huntsman Cancer Hospital, which has been designated as Mastocytosis Center of Excellence. He also runs several clinical trials as the principal investigator in polycythemia vera, essential thrombocythemia, systemic mastocytosis and acute leukemia.

    At the VA Medical Center, he is one of the lead hematologists and cares for all the veterans with acute leukemias, myelodysplastic syndromes and myeloproliferative neoplasms that are referred to Salt Lake City VA from different parts of the Intermountain West. He also leads several research projects.

    To schedule an appointment New Mastocytosis Patients: 801-587-4630. New MPN Patients: (801)646-4122 Returning patients: 801-585-2626 or schedule through MyChart.

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)

    Patient Rating

    Rating: 4.9 out of 5
    4.9 /5
    ( out of 89 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Took his time to explain all I needed to know, and gave me time to ask all my questions and address my concerns.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr.Tashi explains the situation so a lai person can understand very well. He is caring, just a wonderful doctor!

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Outstanding physician, expert in his field.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Tashi show exceptional kindness and concern. He answered important questions posed directly and confidently. He explained the difference between MCAS and Mastocytosis with clarity and inspired confidence that treatment was possible. You have a great physician in Dr. Tashi.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Very knowledgeable and takes the time to cover all aspects of your disease and treatment options.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    He is interested in all aspects of my health

    SOUTH JORDAN HEALTH CENTER
    Rating: 5 out of 5

    Dr. Tashi is wonderful. He cares so much for his patients. You can tell that he loves the work he does and the people he works with. He is so caring and considerate. I love seeing him. He is always so postive that you leave the exam room feeling like you're very valuable.

    SOUTH JORDAN HEALTH CENTER
    Rating: 5 out of 5

    Straightforward and caring, knowing exactly how to treat my diagnosis.

    SOUTH JORDAN HEALTH CENTER
    Rating: 5 out of 5

    Dr Tashi is the most impressive provider I've met in recent history. He's the real deal and knows how to talk with lay people.

  • Dr. Tsewang Tashi joined the University of Utah faculty after completing his hematology/oncology fellowship in 2015. He received his medical degree from Chang Gung University, Taiwan, and completed his internal medicine residency both in Taiwan, and in the US from Creighton University Medical Center, Omaha, NE. Early in his career during fellowship, he has been involved in research with Dr. Josef Prchal on high altitude genetic adaptation, hypoxia signaling and molecular genetics of myeloproliferative neoplasms.

    His research and clinical interest lies in myeloid malignancies and currently sees and manages patients with myeloproliferative neoplasms, including systemic mastocytosis, and acute leukemias, both at the Huntsman Cancer Institute and serving the veterans at the George E. Whalen VA Medical Center in Salt Lake City. He established and currently leads the Mastocytosis Program at the Huntsman Cancer Hospital, which has been designated as Mastocytosis Center of Excellence. He also runs several clinical trials as the principal investigator in polycythemia vera, essential thrombocythemia, systemic mastocytosis and acute leukemia.

    At the VA Medical Center, he is one of the lead hematologists and cares for all the veterans with acute leukemias, myelodysplastic syndromes and myeloproliferative neoplasms that are referred to Salt Lake City VA from different parts of the Intermountain West. He also leads several research projects.

    To schedule an appointment New Mastocytosis Patients: 801-587-4630. New MPN Patients: (801)646-4122 Returning patients: 801-585-2626 or schedule through MyChart.

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Associate Professor (Clinical)
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Internal Medicine)

    Education history

    Professional Medical Medicine - Chang Gung University School of Medicine M.D.
    Internship Internal Medicine - MacKay Memorial Hospital Intern
    Residency Internal Medicine - Pingtung Christian Hospital Resident
    Residency Internal Medicine - Creighton University Resident
    Fellowship Hematology/Oncology - University of Utah Fellow
    Graduate Training Master of Science in Clinical Investigation - University of Utah M.S.C.I

    Selected Publications

    Journal Article

    1. Gangaraju R, Song J, Kim SJ, Tashi T, Reeves BN, Sundar KM, Thiagarajan P, Prchal J (2020). Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood advances, 4(6), 1115-1130. (Read full publication)
    2. Feusier JE, Arunachalam S, Tashi T, Baker MJ, VanSant-Webb C, Ferdig A, Welm BE, Rodriguez-Flores JL, Ours C, Jorde LB, Prchal JT, Mason C (2021). Large-Scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers. Blood cancer discovery, 2(3), 226-237. (Read full publication)
    3. Tashi T, Yu J, Pandya S, Dieyi C, Scherber R, Parasuraman (2023). Trends in overall mortality among US veterans with primary myelofibrosis. BMC cancer, 23(1), 48. (Read full publication)
    4. Chuah YY, Tashi T, Kuo C (2022). An unexpected cause of Cullen's sign: rupture of hepatocellular carcinoma. British journal of hospital medicine (London, England, 83(11), 1. (Read full publication)
    5. Verstovsek S, Mesa R, Mascarenhas J, Tashi T, Shih W, Sato T, Urbanski R, Zagrijtschuk O, Zimmerman (2022). MPN-546 A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia. Clinical lymphoma, myeloma & leukemia, 22 Suppl 2, S342-S343. (Read full publication)
    6. Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, George TI, Panse J, Alvarez-Twose I, Radia DH, Tashi T, Bulai Livideanu C, Sabato V, Heaney M, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schwartz L, Ward BR, Schafhausen P, Vadas P, Bose P, DeAngelo DJ, Rein L, Vachhani P, Triggiani M, Bonadonna P, Rafferty M, Butt NM, Oh ST, Wortmann F, Ungerstedt J, Guilarte M, Taparia M, Kuykendall AT, Arana Yi C, Ogbogu P, Gaudy-Marqueste C, Mattsson M, Shomali W, Giannetti MP, Bidollari I, Lin HM, Sulllivan E, Mar B, Scherber R, Roche M, Akin C, Maurer (2023). Avapritinib versus Placebo in Indolent Systemic Mastocytosis. NEJM evidence, 2(6), EVIDoa2200339. (Read full publication)
    7. Li P, Alnoor FNU, Xie W, Williams M, Feusier J, Ding Y, Zhao X, Zheng G, Zhao C, Zieske AW, Zu Y, Raess PW, Tantravahi S, Osman A, Patel AB, Tashi T, Patel JL, Matynia AP, Menon MP, Miles RR, Jacobsen JR, George TI, Sborov DW, Szankasi P, Rindler P, Close D, Ohgami R (2025). Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS. Leukemia, 39(1), 248-256. (Read full publication)
    8. Yacoub A, Abu-Zeinah G, Qin A, Tashi T, Da'na W, Shih WJ, Zagrijtschuk O, Tsai CY, Geller R, Komatsu N, Mesa R, Gill (2025). PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera. Annals of hematology, (Read full publication)
    9. Madigan LM, Boggs NA, Rets AV, Gru AA, Tashi T, Wada DA, Florell SR, Carter M (2025). Mastocytosis in the Skin: Approach to Diagnosis, Evaluation, and Management in Adult and Pediatric Patients. American journal of clinical dermatology, 26(4), 499-510. (Read full publication)
    10. Masarova L, Reeves BN, El Chaer F, Foltz L, Tashi T, Abu-Zeinah G, Lucas J, Halpern AB, Maze D, Qin A, Safah H, Lan F, O'Connell CL, Goel S, Rein L, Fang B, How J, Babu S, Li Z, Cerquozzi S, Oh ST, Hunter AM, Podoltsev N, Vachhani P, Yacoub A, Cunningham JM, Hillis C, Otoukesh S, Zagrijtschuk O, Castro H, Bose (2025). A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial. Frontiers in medicine, 12, 1548590. (Read full publication)
    11. Mascarenhas J, Bose P, Hillis C, Yacoub A, El Chaer F, Maze D, Abu-Zeinah G, Qin A, Priego V, Tashi T, Cerquozzi S, Babu S, Foltz L, Goel S, Bhave RR, Lee S, Oh ST, Reeves B, Benton C, Fletcher L, Sirhan S, Safah H, Salib H, Villeneuve PJA, Zagrijtschuk O, Castro H, Masarova (2025). ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera. Acta haematologica, 1-7. (Read full publication)

    Review

    1. Tashi (2022). Hematocrit, White Blood Cells, and Thrombotic Events in the Veteran Population With Polycythemia Vera. Federal practitioner, 39(Suppl 2), S43-S46. (Read full publication)
    2. Tashi T, Deininger M (2023). Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms. Immunology and allergy clinics of North America, 43(4), 723-741. (Read full publication)

    Case Report

    1. Chuah YY, Tashi T, Lee YY, Fu TY, Shih CA (2020). Enteropathy-associated T-cell Lymphoma (EATL) with intracranial metastasis : a rare and dismal condition. Acta Gastroenterol Belg, 83(1), 77-80. (Read full publication)

    Editorial

    1. Song J, Tashi T, Prchal J (2019). Editorial Comment on: Inhibition of Suicidal Erythrocyte Death by Chronic Hypoxia by Tang et al. (From: Tang F, Feng L, Li R, Wang W, Liu H, Yang Q, Ge R-L. High Alt Med Biol 2019;20:112-119; DOI: 10.1089/ham.2017.0159). High altitude medicine & biology, 20(2), 120-121. (Read full publication)

    Letter

    1. Mesa R, Yacoub A, Tashi T, Chai-Ho W, Yoon CH, Mascarenhas (2025). Navigating the peginterferon Alfa-2a shortage: practical guidance on transitioning patients to ropeginterferon alfa-2b. Annals of hematology, 104(4), 2571-2573. (Read full publication)

  • News & Podcasts

    Huntsman Cancer Institute News